Posts

FDA Identifies Further Safety Concerns With Intercept’s...

The Food and Drug Administration (FDA) has uncovered additional safety concerns ...

Ro Partners With Eli Lilly to Offer Zepbound, a Weight-...

Ro, a direct-to-consumer health and wellness company, has announced a partnershi...

Small cell lung cancer: Navigating the global clinical ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’...

EMA recommends expanding approval of Ofev to children a...

Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication ...

Denmark’s HTA evolution

New HTA statistics produced by Denmark’s Medicinrådet for 2024 have prompted Glo...

Bavarian Nordic signs mpox vax deal with Serum Institut...

Bavarian Nordic has signed a licence and manufacturing agreement with the Serum ...

GSK’s lung cancer therapy gains EMA PRIME designation

GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for...

ADCs breach barriers to become mainstream cancer treatment

Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) ...

FDA approves Galderma’s Nemluvio to treat atopic dermat...

The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged ...

The future of third-party logistics in an evolving biop...

The biopharmaceutical industry faces a future full of risks and rewards. But wha...

Reprieve for WuXi as Biosecure vote likely pushed to 2025

WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europ...

Risk adjusted net present value: What is the current va...

CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a...

Risk adjusted net present value: What is the current va...

AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Bioscien...

Risk adjusted net present value: What is the current va...

Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with ...

Risk adjusted net present value: What is the current va...

INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading...